Agendia, a world leader in molecular cancer diagnostics, announced that it has received the Clinical Laboratory Permit from the New York State Department of Health. The New York State permit allows the company to receive commercial samples of MammaPrint, its FDA-cleared breast cancer recurrence test. With this latest permit, Agendia has now obtained all major U.S. clinical laboratory licenses...
More...